NUCLEATE
Cluster for Nucleic Acid Sciences and Technologies
About us
NUCLEATE Cluster unites researchers in RNA and DNA biology, gene regulation, structural and chemical biology, bioengineering, computation and translational medicine.
Our mission: advancing the full spectrum of nucleic acid research, from fundamental mechanisms to next generation nucleic acid based therapeutics.
History & Structure
In 2025, NUCLEATE was successfully approved as one of the newly funded Clusters of Excellence under Germany’s Excellence Strategy. The cluster is jointly coordinated by three universities: Ludwig-Maximilians-Universität München (LMU), Technical University of Munich (TUM), and Julius Maximilian University of Würzburg (JMU), with LMU as lead. It partners with Helmholtz Institute for RNA-based Infection Research, Helmholtz Munich, and the Max Planck Institute of Biochemistry. A defining strength of NUCLEATE is its highly interdisciplinary structure.
Research & Focus
NUCLEATE pursues a systematic and innovative approach to nucleic acid research. The aim is to study RNA and DNA molecules not only in their classic role as information storage devices, but also as active regulators and tools. The focus is on three perspectives: nucleic acids as subjects (active molecular actors), as objects (targets of biological regulation), and as tools (basis for therapeutic or technological applications). This conceptual tripartite division allows for a novel structuring of research approaches within the cluster.
More about Research
Future & Talent
2026
Start of Funding
7
Years per Funding Phase (Excellence Strategy)
3
Universities: LMU München, TU Munich & JMU Würzburg
6
Institutions in the Munich-Würzburg Network
“NUCLEATE reflects our shared ambition to drive fundamental research and unite disciplines in building an internationally leading center for nucleic acid science and technologies.”
Prof. Dr. Veit Hornung
“With NUCLEATE, we are empowering the next generation of nucleic acid scientists.”
Prof. Dr. Cynthia Sharma
“NUCLEATE will lay the foundation for a new generation of therapeutics.”
Prof. Dr. Dr. Stefan Engelhardt